Qiming Corporate GP VI, Ltd. sold $5.9M of ALMR (indirect holdings)
Qiming Corporate GP VI, Ltd. sold 217,512 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $27.35 ($26.34–$28.44, $5.95M total) across 16 trades over 2026-10-19 to 2026-10-20. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed sale may prompt short sellers and could slightly depress the stock in the short term.
Market read
A modest insider sell that could generate brief downward pressure on ALMR.
What to watch
Potential upcoming clinical data releases or financing needs not disclosed in the filing.
Background
Form 4 filings disclose insider transactions; Qiming Corporate GP VI is a 10% owner of ALMR.
Ticker impact
Qiming Corporate GP VI sold $5.9M of ALMR shares, reducing its indirect holding to 1.85M shares.
likely downward pressure as the market prices in the insider sell.
A 10% owner sold 217,512 shares at $27.35 average, a material stake reduction that can be interpreted as reduced confidence.
Market effects
Minimal impact on the broader biotech sector; only a single insider transaction.
No regional effect beyond the company's share price.
Limited to investors tracking insider activity in small-cap biotech.
Counterpoint
The sale could be a routine liquidity move unrelated to company fundamentals.
Key entities
- companyAlamar Biosciences, Inc.
Biotech firm whose shares were sold.
- insiderQiming Corporate GP VI, Ltd.
10% owner reporting the sale.
